JAZZ vs. TAK: Jazz Pharmaceuticals vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Jazz Pharmaceuticals (JAZZ) and Takeda Pharmaceutical (TAK) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Jazz Pharmaceuticals (JAZZ) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Jazz Pharmaceuticals (JAZZ) has a non-negative beta of 0.33.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Jazz Pharmaceuticals (JAZZ) at 5.05% and Takeda Pharmaceutical (TAK) at 0.56% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Both Jazz Pharmaceuticals (JAZZ) at 4.37% and Takeda Pharmaceutical (TAK) at 0.87% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Jazz Pharmaceuticals (JAZZ) at 4.88% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while Jazz Pharmaceuticals (JAZZ) at -167.51% is in the bottom quartile, showing a clear gap in earnings momentum.

Growth Metrics

Financial Strength

Both Jazz Pharmaceuticals (JAZZ) at 1.82 and Takeda Pharmaceutical (TAK) at 1.15 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Jazz Pharmaceuticals (JAZZ) at 1.35 and Takeda Pharmaceutical (TAK) at 0.72 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both look expensive on trailing earnings: Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer P/E ratio quartile, and Takeda Pharmaceutical (TAK) at 300.29 is richer still, above its industry range.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Jazz Pharmaceuticals (JAZZ) at 3.19 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile against book while Jazz Pharmaceuticals (JAZZ) at 3.59 is valued near its industry’s middle — TAK is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics